Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47
Document Type and Number:
WIPO Patent Application WO/2023/213290
Kind Code:
A1
Abstract:
Provided is a recombinant fusion protein comprising (a) an anti-CD40 antibody or an antigen binding portion thereof comprising a heavy chain variable region and a light chain variable region, and (b) a CD47 binding domain. Provided is a nucleic acid molecule encoding the recombinant fusion protein, a vector comprising said nucleic acid and a host cell transformed or transfected with said vector or with such a nucleic acid. Furthermore, provided is a process for the production of said recombinant fusion protein, a medical use of said recombinant fusion protein and a kit comprising said recombinant fusion protein.

Inventors:
CHEN MINGJIU (CN)
MA MARK ZHIQING (CN)
WANG YUJIE (CN)
XU JINGJING (CN)
Application Number:
PCT/CN2023/092215
Publication Date:
November 09, 2023
Filing Date:
May 05, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BIOSION INC (CN)
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
C07K14/00; A61P35/00; C07K14/435; C07K19/00
Domestic Patent References:
WO2022061124A12022-03-24
WO2021197335A12021-10-07
WO2020180811A12020-09-10
WO2018233607A12018-12-27
WO2016024021A12016-02-18
Other References:
DE SILVA SURESH, FROMM GEORGE, SHUPTRINE CASEY W., JOHANNES KELLSEY, PATEL ARPITA, YOO KYUNG JIN, HUANG KAIWEN, SCHREIBER TAYLOR H: "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 2, 1 February 2020 (2020-02-01), US , pages 230 - 245, XP093036989, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-19-0493
Download PDF: